Literature DB >> 22599586

Overexpression of human HMW FGF-2 but not LMW FGF-2 reduces the cytotoxic effect of lentiviral gene transfer in human corneal endothelial cells.

Monika Valtink1, Lilla Knels, Nicole Stanke, Katrin Engelmann, Richard H W Funk, Dirk Lindemann.   

Abstract

PURPOSE: Recently, insertion of immuno-modulatory or anti-apoptotic genes into corneal endothelial cells (HCECs) came into focus. Basic FGF-2 occurs in one secreted (low molecular weight, LMW, 18 kD) and four nuclear (high molecular weight, HMW, 22-34 kD) isoforms. HMW isoforms are known differentiation and survival factors, while LMW FGF-2 is a known mitogen. The effect of FGF-2 overexpression of each of the five known isoforms on HCEC cell survival after lentiviral gene transfer in different culture media was investigated.
METHODS: Cells were transduced with lentiviral vectors encoding for each of the five FGF-2 isoforms. Transduction efficiency and expression of individual FGF-2 isoforms was assessed by marker gene transfer and western blotting. Primary HCECs were cultured and transduced in four different media previously described for HCEC cultivation or corneal organ cultivation. Cytotoxic effect of virus infection and a possible rescue effect of FGF-2 overexpression were determined by resazurin conversion assay.
RESULTS: Transduction with FGF-2 encoding lentiviral vectors resulted in overexpression of the respective isoform in all tested cell populations. Western blotting after total cell lysis proved nuclear localization of transgenic HMW isoforms. Overexpression of HMW FGF-2-especially 34 kD FGF-2-reduced lentiviral cytotoxicity, while overexpression of LMW FGF-2 aggravated viral cytotoxicity.
CONCLUSIONS: Cytotoxicity of lentiviral gene transfer in corneal endothelial cells may be reduced by using bicistronic vectors that encode for the target gene and the 34-kD isoform of human FGF-2. Such cotransduction of a survival factor may increase cell survival after gene transfer, thereby improving gene therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22599586     DOI: 10.1167/iovs.12-9423

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

1.  Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.

Authors:  Ana Sahores; Virginia Figueroa; María May; Marcos Liguori; Adrián Rubstein; Cynthia Fuentes; Britta M Jacobsen; Andrés Elía; Paola Rojas; Gonzalo R Sequeira; Michelle M Álvarez; Pedro González; Hugo Gass; Stephen Hewitt; Alfredo Molinolo; Claudia Lanari; Caroline A Lamb
Journal:  Horm Cancer       Date:  2018-06-28       Impact factor: 3.869

2.  Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23.

Authors:  Xiaobin Han; Zhousheng Xiao; L Darryl Quarles
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

3.  Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction.

Authors:  Janet R Manning; Aruna B Wijeratne; Brian B Oloizia; Yu Zhang; Kenneth D Greis; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2020-08-25       Impact factor: 5.000

4.  High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodeling.

Authors:  Jon-Jon Santiago; Leslie J McNaughton; Navid Koleini; Xin Ma; Brian Bestvater; Barbara E Nickel; Robert R Fandrich; Jeffrey T Wigle; Darren H Freed; Rakesh C Arora; Elissavet Kardami
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.